Effects of a novel weight‐loss combination product containing orlistat and acarbose on obesity: A randomized, placebo‐controlled trial

OBJECTIVE: The aim of this study was to evaluate the effect of a novel, oral, modified‐release formulation of the lipase inhibitor orlistat and the glucosidase/amylase inhibitor acarbose (denoted EMP16) on relative body weight after 26 weeks compared with placebo. METHODS: The randomized, double‐bli...

Descripción completa

Detalles Bibliográficos
Autores principales: Holmbäck, Ulf, Grudén, Stefan, Litorp, Helena, Willhems, Daniel, Kuusk, Sandra, Alderborn, Göran, Söderhäll, Arvid, Forslund, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826204/
https://www.ncbi.nlm.nih.gov/pubmed/36123783
http://dx.doi.org/10.1002/oby.23557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826204/
https://www.ncbi.nlm.nih.gov/pubmed/36123783
http://dx.doi.org/10.1002/oby.23557

Ejemplares similares